Guest: Roy Steigbigel, MD
Host: Mark Nolan Hill, MD
We are getting our first in-depth look at some of the research behind raltegravir, a powerful therapy for multi-drug resistant HIV infection already approved by the FDA. How is this raltegravir data impacting current clinical strategies for attacking the virus in multi-drug resistant patients? Host Dr. Mark Nolan Hill probes this question and much more with Dr. Roy Steigbigel, professor of medicine and pathology, molecular genetics and microbiology, and pharmacological sciences, and founding director of the Comprehensive AIDS Center at the State University of New York at Stony Brook.
